REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additi...
June 01 2020 - 8:00AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system disorders, announced today that the
company will hold a webcast on Friday, June 5, 2020 at 8.30 a.m. to
present additional results and analyses from its Phase 3 trial in
negative symptoms. This webcast replaces that previously scheduled
for today (June 1, 2020) announced by the Company on May 29,
2020.
Minerva management will be joined on the webcast by key opinion
leaders Philip Harvey, Ph.D. and Brian Kirkpatrick, M.D. who will
discuss these findings.
Philip D. Harvey, Ph.D. is Leonard M. Miller
Professor of Psychiatry and director of the Division of
Psychology at the University of Miami Miller School of
Medicine and a VA Senior Health Scientist. Dr.
Harvey’s research has focused on cognition and functioning, and he
has written extensively on aging in schizophrenia, negative
symptoms in schizophrenia, functional impairments in severe mental
illness, the cognitive effects of typical and atypical
antipsychotics, and the effects of cognitive enhancing agents and
cognitive training in various conditions. He is the author of over
1,000 scientific papers and abstracts, and he has written over 60
book chapters. Dr. Harvey is a widely cited author who
was repeatedly designated by Thompson-Reuters as being in the top
1% of all researchers in citations in mental health each year since
2010. He has received numerous awards for his research in
schizophrenia.
Brian Kirkpatrick, M.D. is a professor and department chair at
the University of Nevada, Reno School of Medicine Department of
Psychiatry and Behavioral Sciences. He received his M.D. from the
University of Texas Medical School at Houston. He completed his
psychiatry residency at the University of North Carolina, where he
also received a master's in epidemiology. He was on the faculty of
Maryland Psychiatric Research Center at the University of Maryland,
and was Vice Chair of the Department of Psychiatry at the Medical
College of Georgia. He was Chair of the Department of Psychiatry at
Scott & White Healthcare and Texas A&M University College
of Medicine before coming to Nevada. Dr. Kirkpatrick is an
associate editor of Clinical Schizophrenia and Related
Psychoses, serves on the editorial board of Schizophrenia
Bulletin and was co-chair of the National Institute of Mental
Health-sponsored Consensus Development Conference on Negative
Symptoms.
Conference Call Information:
Minerva Neurosciences will host a conference call and live audio
webcast on Friday, June 5, 2020 at 8:30 a.m. Eastern Time to
discuss the Phase 3 trial of roluperidone. To participate, please
dial 1-877-425-9470 (toll free) or 1-201-389-0878
(toll/international), and refer to conference ID 13703481.
To participate in the webcast, please link to:
http://public.viavid.com/index.php?id=139821. The live webcast can
be accessed under “Events and Presentations” in the Investors and
Media section of Minerva’s website at
ir.minervaneurosciences.com. The archived webcast will be
available on the website beginning approximately two hours after
the event for 90 days.
About Minerva Neurosciences
Minerva’s proprietary compounds include: roluperidone (MIN-101),
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking statements
include statements herein with respect to the timing and scope of
future clinical trials and results of clinical trials with
roluperidone (MIN-101); the clinical and therapeutic potential of
this compound; the timing and outcomes of future interactions with
U.S. and foreign regulatory bodies; our ability to successfully
develop and commercialize our therapeutic products; the sufficiency
of our current cash position to fund our operations; and
management’s ability to successfully achieve its goals. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, whether roluperidone will
advance further in the clinical trials process and whether and
when, if at all, it will receive final approval from the U.S. Food
and Drug Administration or equivalent foreign regulatory agencies
and for which indications; whether any of our therapeutic products
will be successfully marketed if approved; whether any of our
therapeutic product discovery and development efforts will be
successful; management’s ability to successfully achieve its goals;
our ability to raise additional capital to fund our operations on
terms acceptable to us; and general economic conditions. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2020, filed with
the Securities and Exchange Commission on May 4, 2020. Copies
of reports filed with the SEC are posted on our website
at www.minervaneurosciences.com. The forward-looking statements in
this press release are based on information available to us as of
the date hereof, and we disclaim any obligation to update any
forward-looking statements, except as required by law.
Contact:William B. BoniVP, Investor
Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617)
600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024